Loading
A phase 3 trial of Mitoxantrone and Tucidinostat (chidamide) in peripheral T-cell lymphomas, run by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., active and no longer recruiting.
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL is a phase 3 interventional study registered as NCT04668690 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd., with 193 participants enrolled, started 2021-04-13 and due to reach its primary completion in 2027-12-30. Interventions recorded: Mitoxantrone Hydrochloride Liposome Injection and Chidamide.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tucidinostat (chidamide), Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares Tucidinostat (chidamide), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma) and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.
Shares Topoisomerase-I inhibitors (and ADC payloads), Cytotoxic chemotherapy and the tag pipeline.
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Cytotoxic chemotherapy and the tag pipeline.
Shares CSPC Pharmaceutical Group, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/